Sort
48,018 grants matching “immunotherapy”
PEDIATRIC ACTG--ACTU
$1,184,741Children'S Hospital Boston · U01 · FY2001 · AI
Immune Function and the Progression to Type 1 Diabetes
$1,184,579Mark A Atkinson · University Of Florida · P01 · FY2009 · AI
OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA
$1,183,560University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · Defense Health Agency
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES
$1,183,489Brigham And Women'S Hospital · P01 · FY2000 · NS
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy
$1,183,038Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2021 · DE
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
$1,182,811Steven Mark Albelda · University Of Pennsylvania · P01 · FY2016 · CA
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
$1,182,811Steven Mark Albelda · University Of Pennsylvania · P01 · FY2012 · CA
Immuno/Immunogene Therapies for Thoracic Malignancies
$1,182,811Steven Mark Albelda · University Of Pennsylvania · P01 · FY2010 · CA
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
$1,182,811Steven Mark Albelda · University Of Pennsylvania · P01 · FY2015 · CA
Multidisciplinary Collaborative Research in NIDDK Program Area Diseases
$1,182,595James Balow · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK
Unlocking evolutionarily latent immune functions for treating disease
$1,182,389Brenda L. Bass · University Of Utah · R01 · FY2020 · CA
Immuno/Immunogene Therapies for Thoracic Malignancies
$1,181,405Steven Mark Albelda · University Of Pennsylvania · P01 · FY2007 · CA
CAP-IT Center for LNP RNA Immunoprevention
$1,180,595Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2022 · CA
Resource for Molecular Imaging Agents in Precision Medicine
$1,179,527Martin G Pomper · Johns Hopkins University · P41 · FY2021 · EB
Novel Molecular Therapies of Prostate Cancer
$1,179,015Dario C. Altieri · Wistar Institute · P01 · FY2019 · CA
Multiscale Mathematical Modeling of Cancer Progression
$1,178,908Vito Quaranta · Vanderbilt University · U54 · FY2014 · CA
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
$1,178,618Douglas F Nixon · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA
Determine the molecular and metabolic mechanisms by which A-FABP links dysregulated lipid metabolism-induced obesity/breast cancer risk
$1,178,523Bing Li · University Of Iowa · U01 · FY2022 · CA
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
$1,178,126Douglas F Nixon · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Metabolic regulation of T cell effector function and anti-tumor immunotherapy
$1,177,923Naomi Taylor · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
ASSESSMENT OF ENDOGENOUS AND CAR T-CELL IMMUNITY FOLLOWING ANTI-PD-1 AGENT AS A TRANSITION STEP TO PHASE 2 COMBINATION IMMUNOTHERAPY
$1,177,565Sloan-Kettering Institute For Cancer Research · · FY2019 · Department of the Army
Immune Function and the Progression to Type 1 Diabetes
$1,177,132Mark A Atkinson · University Of Florida · P01 · FY2010 · AI
Clinical Trials of Patients with AIDS-Related Malignancies
$1,176,741Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
DNA Vaccines
$1,176,511George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
COLUMBIA-ADARC AIDS CLINICAL TRIALS UNIT
$1,176,475Columbia University Health Sciences · U01 · FY2000 · AI